Pan Yuanqing, Wang Renjie, Zhang Fengwa, Chen Yonglin, Lv Qingfang, Long Ge, Yang Kehu
Institute of Medical Psychology, Evidence-Based Medicine Center, Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, School of Basic Medical Sciences Lanzhou, Gansu, China.
Department of Clinical Laboratory, Pingjin Hospital, Logistics College of Armed Police Forces Tianjin, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):384-93. eCollection 2015.
MiR-130a has been demonstrated to play important roles in many types of cancers. Nevertheless, its biological function in breast cancer remains largely unknown. In this study, we found that the expression level of miR-130a was down-regulated in breast cancer tissues and cells. Overexpression of miR-130a was able to inhibit cell proliferation, invasion and migration in MCF7 and MDA-MB-435 cells. With the bioinformatics analysis, we further identified that RAB5A was a directly target of miR-130a, and its mRNA and protein level was negatively regulated by miR-130a. Immunohistochemistry verified RAB5A was upregulated in breast cancer tissues. Therefore, the data reported here demonstrate that miR-130a is an important tumor suppressor in breast cancer, and imply that miR-130a/RAB5A axis have potential as therapeutic targets for breast cancer.
MiR - 130a已被证明在多种癌症中发挥重要作用。然而,其在乳腺癌中的生物学功能仍 largely未知。在本研究中,我们发现miR - 130a在乳腺癌组织和细胞中的表达水平下调。miR - 130a的过表达能够抑制MCF7和MDA - MB - 435细胞的增殖、侵袭和迁移。通过生物信息学分析,我们进一步确定RAB5A是miR - 130a的直接靶点,其mRNA和蛋白质水平受到miR - 130a的负调控。免疫组织化学证实RAB5A在乳腺癌组织中上调。因此,此处报道的数据表明miR - 130a是乳腺癌中的一种重要肿瘤抑制因子,并暗示miR - 130a/RAB5A轴有作为乳腺癌治疗靶点的潜力。